Idarubicin HCl , ≥98% , 57852-57-0

Synonym(s):
(7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione;4-Demethoxydaunorubicin hydrochloride;DMDR;Idamycin;IMI-30

CAS NO.：57852-57-0

Empirical Formula: C26H28ClNO9

Molecular Weight: 533.95

MDL number: MFCD00897212

EINECS: 260-990-7

PRODUCT Properties

• Melting point: 183-185 C
• alpha: D20 +205° (c = 0.1 in methanol) (Arcamone); D20 +188° (c = 0.10 in methanol) (Kimura)
• storage temp.: Inert atmosphere,2-8°C
• solubility: ≥26.7 mg/mL in DMSO; insoluble in EtOH; ≥2.39 mg/mL in H2O with ultrasonic
• form: solid
• color: Orange to red
• Stability: Hygroscopic, Light Sensitive
• InChIKey: JVHPTYWUBOQMBP-RVFAQHLVSA-N
• SMILES: C12=C(O)C3=C(C(=O)C4C=CC=CC=4C3=O)C(O)=C1C[C@@](O)(C(=O)C)C[C@]2([H])O[C@@H]1O[C@H]([C@@H](O)[C@@H](N)C1)C.Cl |&1:19,25,28,30,31,33,r|

Description and Uses

Idarubicin hydrochloride is a derivative of daunorubicin indicated for acute nonlymphocytic leukemia, acute lymphocytic leukemia, and acute myeloid leukemia. Compared with daunorubicin, idarubicin hydrochloride is less cardiotoxic, has milder side effects, is orally active and more potent in experimental leukemias. Idarubicin hydrochloride is also reportedly active in daunorubicin-resistant patients, breast cancer,Hodgkin's and non-Hodgkin's lymphoma.

Idarubicin HCl is a hydrochloride salt form of Idarubicin which is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells with IC50 of 3.3 ng/mL

Safety

• Symbol(GHS): GHS06,GHS08
• Signal word: Danger
• Hazard statements: H300-H351-H360
• Precautionary statements: P201-P280-P301+P330+P331+P310-P308+P313
• Hazard Codes: T+,Xn
• Risk Statements: 60-61-28-40
• Safety Statements: 53-45-36-22
• RIDADR: UN 2811
• WGK Germany: 3
• RTECS: HB7877000
• HS Code: 2941906000